Anavex Life Sciences Corp. (AVXL) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Anavex (AVXL) Q4 2025: 17.8 Months Functional Delay in Alzheimer’s Drives EMA Re-Examination Push
November 25, 2025
-
Anavex Life Sciences (AVXL) Q3 2025: $101M Cash Runway Extends Over 3 Years as EMA Decision Nears
August 12, 2025
-
Anavex (AVXL) Q2 2025: $115.8M Cash Extends Runway as Schizophrenia Data and EU Alzheimer’s Decision Loom
July 06, 2025